ImmuPharma's Lupuzor OKed to start Phase III and fast-tracked by US FDA
UK-based ImmuPharma plc (LSE:IMM), which last month regained rights to its investigational lupus drug candidate Lupuzor (IPP-201101) from Cephalon, now part of Teva (The Pharma Letter October 24) has provided an update on the drug’s development status.
Commenting on the prospects for Lupuzor, ImmuPharma’s chief executive Dimitri Dimitriou, said: “We are excited about the prospects of Lupuzor, its progress in development and the approvals of the authorities in the USA, Europe and Japan regarding its progression to the final stage of testing. The interest we are seeing already from pharma companies as potential partners gives us great confidence.” ImmuPharma is now in discussions with pharmaceutical companies for a corporate deal regarding Lupuzor, the company noted.
Specifically, the company said:
• An “End of Phase II” meeting package with ImmuPharma’s Phase IIb data was submitted to the US Food and Drug Administration and the FDA responded to all the questions.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze